Multiple Sclerosis Market, [By Drug Type, (Immunosuppressant’s (Lemtrada, Ocrelizumab, Zinbryta, and Aubagio); Immunomodulators (Ampyra, Copaxone, Betaseron/Extavia, Gilneya, Avonex/Plegridy, Tysabri, Rebif, Tecifidera)); By Route of Administration (Injectable agents, Oral agents)]; and Geography - Trend, Analysis and Forecast till 2025

Report Summary

全球多发性硬化症市场规模主要是受市场参与者之间为探索全球未开发市场机会而整合数量增加等因素所驱动的。

多发性硬化（MS）是一种神经和脊髓绝缘层受损的疾病。这些损伤破坏了神经系统的功能，导致双目、肌肉无力、一眼失明和感觉协调障碍。MS的病因尚不清楚，但其机制可能是破坏免疫系统，要么是体内髓鞘生成细胞的失败。一般来说，MS是以症状、症状和支持医学检查结果来诊断的。

Multiple Sclerosis is of four types namely; ‘Relapsing-remitting multiple sclerosis’ (RRMS), ‘Secondary-Progressive Multiple Sclerosis’ (SPMS), ‘Primary-Progressive Multiple Sclerosis (SPMS)’, and ‘Progressive-Relapsing Multiple Sclerosis’ (PRMS). The Secondary-progressive multiple sclerosis is the most common type of MS, generally caused in the adults between 15-60 years of age. Similarly, the children and teenagers can also be affected by the paediatric MS, it is estimated that approximately 10,000 children and teen are diagnosed with MS and had almost one symptom of this disease. In addition, The Multiple Sclerosis Foundation reported approximately 2.5 million of people are suffering from MS globally.

不断发展的竞争格局，增加研究和开发，以了解多发性硬化的根本原因，并提高所有年龄组对多发性硬化的认识，以支持全球范围内的这一市场的发展

The growth in global multiple sclerosis market is primarily driven by increasing number of individuals suffering from multiple sclerosis. In addition, some notable changes in recent past for the treatment of the RRMS, and continuous drug development for treating multiple sclerosis is also expected to aid the growth in this market. Moreover, oral drugs like Aubagio in 2012-2013 were launched as they have proper role in treating multiple sclerosis for various age groups and there is preference shift towards different and sedentary life style. These factors coupled with the improving healthcare infrastructure in the developing economies will surge the global market for multiple sclerosis during the forecast period.

However, the cost of the treatment, and unawareness about the causes if MS might hinder the growth of this market during the forecast period.

全球多发性硬化症市场分类

The worldwide multiple sclerosis market size is segmented on the basis of drug type, route of administration, and geography.

根据药品类型，市场分为：

• Immunosuppressant’s
  • Lemtarda
  • Ocrelizumab
  • Zinbryta
  • 特立氟胺
• Immunomodulators
  • Ampyra
  • Capxone
  • Betaseron/Extavia
  • Gilneya
  • Avonex/Plegridy
  • Tyasabri
  • Rebif
  • Teucifidera

给药途径类型的基础上,马克et is segmented into:

• 可注射剂
• 口服制剂

Multiple Sclerosis market, by drug type is majorly categorized into immunosuppressant’s, and immunomodulators

Increasing number of changes in understanding multiple sclerosis to boost immunomodulators market in the global market.

免疫调节器部分进一步细分为安培拉、卡普逊、贝塔森/埃特维亚、吉尔尼娅、阿沃尼/普莱格、泰萨布里、雷比夫和条西菲德等，全球免疫调节剂市场主要是由于对生物药物的使用越来越偏好和认识，因为它们是某些药物中最有效的治疗方法去年。因此，生物制品的偏好增加将在预测期内刺激多发性硬化症市场免疫调节剂市场。

Geographically, the global market is categorized into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

增加研发支出，开发新的有效治疗多发性硬化（MS）以导致多发性硬化in North America region.

预计北美将在预测期内主导多发性硬化症市场份额。由于市场上大量的参与者不断研发，它占据了主要份额。此外，越来越多的人更倾向于生物药物来促进北美市场。

However, Asia Pacific to grow at a faster pace due to increased awareness for the diagnosis of multiple sclerosis, and developing healthcare infrastructure of the developing countries like China, Japan, and India.

Key players in the global multiple sclerosismarket are:

• Hoffmann-La Roche Ltd.
• 拜耳医药保健乐动娱乐官网股份公司
• Teva Pharmaceuticals
• GlaxoSmithKline
• AbbVie Inc.
• Sonafi Pasteur
• Pfizer Inc.
• Merck & Company
• 诺华
• AB科学
• 欧佩xa